MedPath

SkinPen Efficacy on Acne Scars on the Face and/or Back

Not Applicable
Completed
Conditions
Atrophic Acne Scar
Registration Number
NCT02646917
Lead Sponsor
Bellus Medical, LLC
Brief Summary

This single-center, clinical trial will take place over a 90 day course followed by 1-month and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen device when used on both men and women on the face and/or back.

Detailed Description

At least 20 subjects of varying Fitzpatrick skin types will be admitted to the trial for treatment on their moderate to severe acne scars on the face and/or back. Implementation of needle depths ranging from 0.25 mm to 2.0 mm will depend on severity of scars and their location. Each subject will undergo 3 treatments in 30 day increments and will take pre-treatment images as well as 1-month and 6-months post treatment images. Assessment will be based on the Goodman and Baron's grading system, the Clinician's Global Aesthetic Improvement Scale, as well as a self-assessment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria
  • Men and women 18 to 60 years of age.
  • Subjects in good health.
  • Approximately 5 to 10 atrophic acne scars of mixed types (boxcar and/or rolling scars with some icepick scars allowed) on face and/or back that are moderate to severe.
  • Desire correction of his/her acne scarring.
  • Subjects of child bearing potential must take a urine pregnancy test and must test negative.
  • Subjects willing to sign a photography release.
  • Willingness to cooperate and participate by following study requirements.
Exclusion Criteria
  • Allergies to facial or general skin care products
  • Presence of an active systemic or local skin disease.
  • Severe solar elastosis.
  • Sensitivity to topical lidocaine.
  • Recent history of significant trauma to the face (< 6 months).
  • Significant scarring other than acne scars in treated area(s).
  • Severe of cystic active and clinically significant acne on the area(s) to be treated.
  • History of systemic granulomatous diseases.
  • History of hypertrophic or keloid scars.
  • Current cancerous or pre-cancerous lesions in area(s) to be treated.
  • Had microdermabrasion or glycolic acid treatment to treatment area(s) within 1 month prior to study participation.
  • History of chronic drug or alcohol abuse.
  • Current smokers or have smoked in the last 5 years.
  • History of cosmetic treatments: Skin tightening within last year, injectable filler of any type within the last year, neurotoxins within the last 3 months, ablative resurfacing laser treatments, non-ablative, rejuvanative laser treatments in last 6 months, chemical peel, dermabrasion, non-ablative laser or fractional laser resurfacing of face and neck within the last 4 weeks.
  • History of certain prescription medications (accutane or other retinoids, topical retinoids, prescription strength skin lightening devices, anti-wrinkle, skin lightening devices, antiplatelet agents/Anticoagulants, and/or psychiatric drugs).
  • Nursing, pregnant, or planning to become pregnant during study.
  • Current or pre-existing dermatologic diseases on the face or body (psoriasis, rosacea, eczema, etc.)
  • History of immunosupression/immune deficiency disorders.
  • Current or history of uncontrolled disease such as asthma, diabetes, hyperthyroidism, etc.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Clinician's Global Aesthetic Improvement Assessment (CGAIS)1 month post treatment, and 6 months post treatment

Clinician's Global Aesthetic Improvement Assessment:

minimal score is 1- Very much improved and, maximum score is 5 -Worse: The appearance is worse than the original condition

Severity of Acne ScarsBaseline, 1 month post treatment, and 6 months post treatment

Goodman and Baron's Qualitative grading system. Possible scores range from 1 = mild to 4 = severe.

Secondary Outcome Measures
NameTimeMethod
Subject Self-Assessment Using SASISOne Month Post Treatment, 6 Month Post Treatment

Subject self-assessment was completed in 2 steps for self-assessed scar improvement scale (SASIS) and subject global aesthetic improvement scale (SGAIS):

1. Based on a live assessment (subjects were provided with a hand mirror for assessment) of the subject while referring to pre-treatment images.

2. Based on a comparison of pre-treatment images to current post-treatment images. Rating of Acne Scars

* 1-Exacerbation of acne scars 0 No change in the appearance of acne scars

1. 1% - 25% improvement in the appearance of acne scars

2. 25% - 50% improvement in the appearance of acne scars 3-50% - 75% improvement in the appearance of acne scars 4-75% - 99% improvement in the appearance of acne scars

Photo Grading of Acne Scar AssessmentDay 1 (Baseline), Day 30, Day 60, 1-Month post treatment and 6 Month post treatment

Photo grading of acne scars assessment was done using the following scale \[Karnik J. et al, JAAD 2014, 71 (1)\]:

Grade- Term- Description

0 - Clear-- No depression is seen in the treatment area. Macular discoloration may be seen.

1. - Very mild- - A single depression is easily noticeable with direct lighting (deep). Most or all of the depressions seen are only readily apparent with tangential lighting (shallow).

2. - Mild-- A few to several, but less than half of all the depressions are easily noticeable with direct lighting(deep). Most of the depressions see are only readily apparent with tangential lighting (Shallow)

3- Moderate-- More than half of the depressions are apparent with direct lighting (deep)

4- Severe-- All or almost all the lesions can be seen with direct lighting (deep)

Subject Self-Assessment Using Global Aesthetic Improvement Scale (SGAIS)1-Month Post Treatment and 6- Month Post Treatment

The following rating scale was used for SGAIS:

Rating and Description

1. - Very much improved: Optimal cosmetic result

2. - Much improved: Marked improvement in appearance from the initial condition, but not completely optimal

3. - Improved: Obvious improvement in appearance from initial condition

4. -No change: The appearance is essentially the same as the original condition

5. - Worse: The appearance is worse than the original condition

Trial Locations

Locations (1)

Stephens & Associates

🇺🇸

Richardson, Texas, United States

Stephens & Associates
🇺🇸Richardson, Texas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.